130 results
15F-12B
EX-99.1
CLYYF
Celyad Oncology SA
9 Feb 24
Securities registration termination (foreign)
6:07am
beliefs about and expectations for the Company’s updated strategic business model, including associated potential benefits, transactions and partnerships … ; the Company’s ability to realize the expected benefits of its updated strategic business model; the Company’s ability to develop its IP assets
6-K
EX-99.1
CLYYF
Celyad Oncology SA
17 Jan 24
Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook
6:33am
model, including associated potential benefits, transactions and partnerships, statements regarding the potential value of the Company’s IP … the expected benefits of its updated strategic business model; the Company’s ability to develop its IP assets and enter into partnerships
6-K
EX-99.1
CLYYF
Celyad Oncology SA
21 Dec 23
Publication of a transparency notification received from Fortress Investment Group LLC
6:19am
for the Company’s updated strategic business model, including associated potential benefits, transactions and partnerships, statements regarding … ability to realize the expected benefits of its updated strategic business model; the Company’s ability to develop its IP assets and enter
6-K
EX-99.1
CLYYF
Celyad Oncology SA
18 Dec 23
Current report (foreign)
12:29pm
potential benefits, transactions and partnerships, statements regarding the potential value of the Company’s IP, and statements regarding the continuation … the expected benefits of its updated strategic business model; the Company’s ability to develop its IP assets and enter into partnerships with outside
6-K
EX-99.1
CLYYF
Celyad Oncology SA
4 Dec 23
Celyad announces management change
1:28pm
benefits of its updated strategic business model; the Company’s ability to develop its IP assets and enter into partnerships with outside parties
6-K
EX-99.1
f8z2hwobxp o9eq85k9
4 Dec 23
Current report (foreign)
1:26pm
6-K
EX-99.1
43rr8b85wth gwu
24 Nov 23
Celyad Oncology reports third quarter 2023 financial
8:54am
6-K
EX-99.1
hojx qq00zqj5dw8
21 Nov 23
Publication of a transparency notification received from
4:05pm
6-K
EX-99.1
j2yzvtv01ge wa
15 Nov 23
Information on the Total Number of Voting Rights and Total Number of shares with single voting rights
4:37pm
6-K
EX-99.1
18f11l9dwgmaziqtn ae
27 Oct 23
Current report (foreign)
1:45pm
6-K
EX-99.1
k0a61oh8f5f
26 Sep 23
Celyad Oncology Announces the Termination of Its American Depository
6:06am
6-K
EX-99.1
st87r4hvjv6zk
22 Sep 23
Current report (foreign)
6:06am
6-K
EX-99.1
h64bjtni
18 Sep 23
Publication of a rectified transparency notification received from
6:04am
6-K
EX-99.1
9iths
13 Sep 23
Current report (foreign)
6:29am
6-K
EX-99.1
8y3twwi
11 Sep 23
Publication of a transparency notification received
6:21am
6-K
EX-99.1
8eyougjb416cb6v
6 Sep 23
Current report (foreign)
6:04am
6-K
EX-99.1
av55kp6m1f1zub2b412
5 Sep 23
Celyad Oncology Reports First Half 2023 Financial
6:12am
6-K
EX-99.2
kab4rs
5 Sep 23
Celyad Oncology Reports First Half 2023 Financial
6:12am
6-K
EX-10.3
jvvr 8srs1
25 Aug 23
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
6:07am
6-K
EX-99.1
ne3xmqkhqbt19
25 Aug 23
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
6:07am